COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

Search

Hims & Hers Health Inc

Fechado

SetorConsumo Básico

64.47 10.15

Visão Geral

Variação de preço das ações

24h

Atual

Mín

57.38

Máximo

64.77

Indicadores-chave

By Trading Economics

Rendimento

23M

49M

Vendas

105M

586M

P/E

Médio do Setor

81.191

42.52

EPS

0.2

Margem de lucro

8.444

Funcionários

1,637

EBITDA

39M

58M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-25.56% downside

Dividendos

By Dow Jones

Próximos Ganhos

4 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.2B

12B

Abertura anterior

54.32

Fecho anterior

64.47

Sentimento de Notícias

By Acuity

20%

80%

16 / 151 Ranking em Consumer defensive

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Hims & Hers Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2025, 12:54 UTC

Grandes Movimentos do Mercado

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4 de abr. de 2025, 22:38 UTC

Ações em Alta

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 de abr. de 2025, 23:15 UTC

Grandes Movimentos do Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 de fev. de 2025, 15:33 UTC

Grandes Movimentos do Mercado

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 de nov. de 2024, 19:07 UTC

Grandes Movimentos do Mercado

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 de out. de 2024, 15:02 UTC

Grandes Movimentos do Mercado

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 de out. de 2024, 11:28 UTC

Grandes Movimentos do Mercado

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

7 de mai. de 2025, 13:56 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6 de mai. de 2025, 14:24 UTC

Ganhos

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30 de abr. de 2025, 09:30 UTC

Principais Notícias

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2 de abr. de 2025, 16:53 UTC

Principais Notícias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 de mar. de 2025, 15:54 UTC

Principais Notícias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 de fev. de 2025, 23:20 UTC

Ganhos

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 de fev. de 2025, 12:00 UTC

Principais Notícias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 de dez. de 2024, 17:16 UTC

Principais Notícias

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 de dez. de 2024, 15:14 UTC

Principais Notícias

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 de dez. de 2024, 15:02 UTC

Principais Notícias

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 de dez. de 2024, 13:47 UTC

Principais Notícias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 de dez. de 2024, 07:00 UTC

Principais Notícias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 de out. de 2024, 14:45 UTC

Principais Notícias

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 de out. de 2024, 13:12 UTC

Principais Notícias

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 de out. de 2024, 11:45 UTC

Principais Notícias

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 de out. de 2024, 10:14 UTC

Principais Notícias

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 de ago. de 2024, 17:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 de jun. de 2024, 11:00 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 de mai. de 2024, 20:37 UTC

Ganhos

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Comparação entre Pares

Variação de preço

Hims & Hers Health Inc Previsão

Preço-alvo

By TipRanks

-25.56% parte inferior

Previsão para 12 meses

Média 45.5 USD  -25.56%

Máximo 85 USD

Mínimo 25 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Hims & Hers Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

14 ratings

4

Comprar

8

Manter

2

Vender

Pontuação Técnica

By Trading Central

36.685 / 52.35Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

16 / 151 Ranking em Consumo Básico

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.